Minister U T Khader’s daughter Hawwa Naseema to represent India at Dubai Int’l Quran Contest

Bengaluru, May 9: Karnataka government in its latest order has allowed restaurants, pubs and bars to sell liquor at retail prices from May 9 till May 17. The third phase of coronavirus lockdown is slated to end on May 17.

"Karnataka government has allowed restaurants, pubs and bars to sell liquor at retail prices from tomorrow till May 17. However, they can be sold only in take away form," read an order issued by the state government.

Earlier, the government had allowed the opening of liquor shops in order to mobilise revenue. However, bars, pubs, restaurants were ordered to remain close amid the COVID-19 lockdown.

As per the latest update by the State Health Department, the total number of coronavirus cases in the state is 753. "Of 753 cases, 346 are active cases. 376 persons were discharged after treatment while 30 people have succumbed to the coronavirus," the Health Department said in a release. 

Wayanad, Jul 6: DM Education and Research Foundation (DMERF), headed by Dr Azad Moopen, has come forward to handover DM WIMS Medical College, Nursing and Pharmacy Colleges and its associated institutions in Wayanad to the Kerala Government. 

According to Azad Moopen, Managing Trustee, DMERF, the Kerala Government has been deliberating to set up a medical college in the area over the last 7-8 years to address the challenges being faced by the local population due to lack of local availability of advanced healthcare facilities under the government sector. 

The handover by DMERF would address the Government's need. DM WIMS is one of the few NABH accredited medical colleges in the country, he said.

The DM WIMS Medical College and its associated institutions were established by the DMERF Trust 10 years ago to help the backward community of the district. 

Run in a charitable manner, the medical college has a capacity of 150 seats and has seen two batches of doctors graduate from the institution. With a total built up area of 14 lakh sq feet, it also has a 700-bed super-specialty hospital catering to the local community and helping in training healthcare professionals, a 100-bed specialty hospital, a pharmacy college, and a nursing college.

A new medical college by the government will require substantial investments and minimum of 5 years to become functional. “We think that DM WIMS can cater to the requirement of the government and setting up another medical college might not be required to cater to the existing population,” he said.

Moopen also announced a donation of Rs 250 crore out of the total investment in the institutions to the government to provide treatment to the needy population in the backward, landlocked district and to train good quality doctors from the State.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.